The Wyden letter urges CMS to “conduct immediate oversight and rigorous regulatory enforcement of specific Medicare Part D program requirements for plan sponsors and their PBMs.”
The Biosimilars Council is calling for inclusion of an affirmative statement to allow for a better understanding of treatment options and more affordable medicines.
